In a view of the fact that in clinical practice we have no antidepressants acting by the nonaminergic mechanism, it is necessary to make the most of possibilities given by available antidepressant. At fi rst we can positively infl uence compliance by stressing the patient participation on the treatment. The therapy should especially consider which side effects are acceptable for the individual patient. A small probe examining how much information about treatment is given to the patient and how much they can decide about treatment shows that there is a great space for improving the actual situation. Further possibilities are given by the availability of the new galenic forms and specifi c antidepressants.

        Key words: nonaminergic mechanisms, information of therapy, galenic formulations of antidepressants, availability of specifi c antidepressants, participation of patient in decision-making.